Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Mar 22, 2011

Premium

Phalanx Biotech Group last week launched its Rat Whole Genome OneArray for gene expression profiling.

The chip's content is curated from the RefSeq and Ensembl databases. It includes 25,338 long oligonucleotide probes engineered to meet isothermal requirements for hybridization performance. Phalanx claims the chip offers "high correlation" with quantitative PCR. The Taiwanese firm added that the array enables the interrogation of pathways observed in rat disease models and animal drug metabolism and pharmacokinetics studies.


Skyline Diagnostics last week launched its AMLprofiler for clinical use in Europe.

The test, which runs on the Affymetrix GeneChip platform, allows users to classify individual acute myeloid leukemia patients into different risk categories. Within four days, AMLprofiler can identify AML subtypes in order to help clinicians select the appropriate method of treatment, Skyline said.

BioArray News spoke with Skyline officials about the test last week (BAN 3/15/2011).

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.